CoChat

A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects

Open access
Qureshi, Sajjad A., Rios Candelore, Mari, Xie, Dan, Yang, Xiaodong, Tota, Laurie M., Ding, Victor D.-H., Li, Zhihua, Bansal, Alka, Miller, Corin, Cohen, Sheila M., Jiang, Guoqiang, Brady, Ed, Saperstein, Richard, Duffy, Joseph L., Tata, James R., Chapman, Kevin T., Moller, David E., Zhang, Bei B. · 2004 · Diabetes
Cited by 109

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Glucagon maintains glucose homeostasis during the fasting state by promoting hepatic gluconeogenesis and glycogenolysis. Hyperglucagonemia and/or an elevated glucagon-to-insulin ratio have been reported in diabetic patients and animals. Antagonizing the glucagon receptor is expected to result in reduced hepatic glucose overproduction, leading to overall glycemic control. Here we report the discovery and characterization of compound 1 (Cpd 1), a compound that inhibits binding of 125I-labeled glucagon to the human glucagon receptor with a half-maximal inhibitory concentration value of 181 ± 10 nmol/l. In CHO cells overexpressing the human glucagon receptor, Cpd 1 increased the half-maximal effect for glucagon stimulation of adenylyl cyclase with a KDB of 81 ± 11 nmol/l. In addition, Cpd 1 blocked glucagon-mediated glycogenolysis in primary human hepatocytes. In contrast, a structurally related analog (Cpd 2) was not effective in blocking glucagon-mediated biological effects. Real-time measurement of glycogen synthesis and breakdown in perfused mouse liver showed that Cpd 1 is capable of blocking glucagon-induced glycogenolysis in a dosage-dependent manner. Finally, when dosed in humanized mice, Cpd 1 blocked the rise of glucose levels observed after intraperitoneal administration of exogenous glucagon. Taken together, these data suggest that Cpd 1 is a potent glucagon receptor antagonist that has the capability to block the effects of glucagon in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diabetes.53.12.3267

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 109

Metadata

Authors
Qureshi, S. A., Rios Candelore, M., Xie, D., Yang, X., Tota, L. M., Ding, V. D.-H., Li, Z., Bansal, A., Miller, C., Cohen, S. M., Jiang, G., Brady, E., Saperstein, R., Duffy, J. L., Tata, J. R., Chapman, K. T., Moller, D. E., & Zhang, B. B.
Venue
Diabetes
Published
2004-12-01
Volume
53
Issue
12
Pages
3267-3273
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2116862105
Cited by
109
References
4
FWCI
3.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects. https://app.cochat.ai/papers/10.2337/diabetes.53.12.3267
The paper
Qureshi, S. A., Rios Candelore, M., Xie, D., Yang, X., Tota, L. M., Ding, V. D.-H., Li, Z., Bansal, A., Miller, C., Cohen, S. M., Jiang, G., Brady, E., Saperstein, R., Duffy, J. L., Tata, J. R., Chapman, K. T., Moller, D. E., & Zhang, B. B. (2004). A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects. Diabetes. https://doi.org/10.2337/diabetes.53.12.3267

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.